---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-131920"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:08:55.594999+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corvus Pharmaceuticals raises $30.2M in registered direct offering with CEO participation

## Summary
- Entered Securities Purchase Agreement on May 1, 2024 to issue ~13.5M shares and warrants at $1.7312 per combined unit
- Net proceeds expected ~$30.2M; closing expected May 6, 2024
- Common warrants exercisable at $3.50/share, expiring June 30, 2025
- CEO and existing institutional investors participated in the offering
- Proceeds to be used for working capital, R&D, and general corporate purposes

## SEC filing metadata
- accession: 0001193125-24-131920
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000119312524131920/0001193125-24-131920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000119312524131920/d790042d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-131920
- JSON: https://secwatch.observer/filing/0001193125-24-131920.json
- Plain text: https://secwatch.observer/filing/0001193125-24-131920.txt

## Key facts
- Material Agreements
  Corvus Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein, including the companys chief executive officer and certain of the companys existing institutional investors, including investors affiliated with certain of the companys directors (collectively, the Investors ) valued at combined offering price of $1.7312 (effective 2024-05-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the investors named therein, including the companys chief executive officer and certain of the companys existing institutional investors, including investors affiliated with certain of the companys directors (collectively, the Investors )
  - Value: combined offering price of $1.7312
  - Effective: 2024-05-01
  source text: On May 1, 2024, Corvus Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein, including the Company’s chief executive officer and certain of the Company’s existing institutional investors, including investors affiliated with certain of the Company’s directors (collectively, the “Investors”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000119312524131920/0001193125-24-131920-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.